Abbott & Novo Nordisk India Join Forces to Launch New Semaglutide Brand “Extensior” and Expand Diabetes Care Access
Diabetes care in India is set for a major expansion as Abbott and Novo Nordisk India have announced a strategic partnership to introduce a second brand of the GLP‑1 diabetes treatment semaglutide marketed globally as Ozempic under the name Extensior . Abbott and Novo Nordisk India collaborate to launch Extensior, a second semaglutide brand to expand diabetes care access across India. Under this collaboration, Abbott will leverage its extensive distribution network across India to commercialise Extensior and reach a broader range of patients beyond the urban centres where Novo Nordisk has traditionally focused. What Is Extensior and Why It Matters Extensior is a once‑weekly semaglutide injection approved as an adjunct to diet and exercise to manage blood glucose levels in adults living with type 2 diabetes . Semaglutide a GLP‑1 receptor agonist has shown significant benefits in lowering HbA1c, aiding weight control, and reducing risks of heart ...